Pancreatic Cancer Research

ResearcherHuazhong University of Science and TechnologyNo recent work listed

Xuan Cao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9713-4192; OpenAlex author ID A5003198921. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper

Papers 3

  1. Blockade of DDR1/PYK2/ERK signaling suggesting SH2 superbinder as a novel autophagy inhibitor for pancreatic cancer. Co-author DOI 10.1038/s41419-023-06344-4↗
  2. Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ctm2.337↗
  3. Rigidity controls human desmoplastic matrix anisotropy to enable pancreatic cancer cell spread via extracellular signal-regulated kinase 2. Co-author DOI 10.1016/j.matbio.2018.11.001↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hui Xu · 2 shared papers, 2021–2023 · strength 0.33
  2. Andong Liu · 2 shared papers, 2021–2023 · strength 0.33
  3. Janusz Franco‐Barraza · 1 shared paper, 2019 · strength 0.09
  4. R. Malik · 1 shared paper, 2019 · strength 0.09
  5. Peter I. Lelkes · 1 shared paper, 2019 · strength 0.09
  6. Edna Cukierman · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.